4890-63-5

Usage

Uses

Used in Pharmaceutical Industry:
Phenylacetylenemagnesium chloride is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its ability to participate in nucleophilic addition and alkylation reactions allows for the creation of a diverse array of drug molecules, contributing to the development of new treatments and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, phenylacetylenemagnesium chloride is employed as a crucial building block in the synthesis of agrochemicals. Its reactivity in organic synthesis enables the production of a variety of compounds used in pesticides, herbicides, and other agricultural chemicals, enhancing crop protection and yield.
Used in Material Science:
Phenylacetylenemagnesium chloride is used as a versatile reagent in the development of new materials. Its potential applications in material science are being explored due to its unique reactivity, which can lead to the creation of novel materials with improved properties for various applications.
Used in Research and Development:
Phenylacetylenemagnesium chloride is used as a research compound for studying its potential applications in the synthesis of new pharmaceuticals and materials. Its reactivity and stability make it an attractive candidate for exploring new reaction pathways and discovering innovative compounds with potential applications in various industries.

Upstream product

• 536-74-3 phenylacetylene 

Downstream Products

• 1883-26-7 phenyl[di(phenylethynyl)]phosphine sulfide 
• 130307-88-9 2-Hydroxy-4-phenyl-2-trifluormethylbut-3-insaeureethylester 
• 591-50-4 iodobenzene 
• 55009-90-0 (pentafluorobut-1-yn-1-yl)benzene 
• 92981-89-0 (Phenylethinyl)phosphan 
• 1817-49-8 1,3-diphenyl-1-propyn-3-ol 
• 615253-71-9 1-(1,3-diphenylprop-2-yn-1-yl)pyrrolidine 
• 718-30-9 4-Dimethylamino-4-methyl-1-phenylpent-1-yne 
• 886-66-8 1,4-diphenyl-1,3-butadiyne 
• 76173-73-4 3-Chlor-1,3-diphenyl-1-propin 
• 84384-29-2 5-<(E)-α-Chlorbenzyliden>-endo-6-phenylbicyclo<2.2.1>hept-2-en 
• 84384-29-2 5-<(Z)-α-Chlorbenzyliden>-endo-6-phenylbicyclo<2.2.1>hept-2-en 
• 84384-29-2 5-<(E)-α-Chlorbenzyliden>-exo-6-phenylbicyclo<2.2.1>hept-2-en 

Relevant academic research and scientific papers

Regioselective 1,4-conjugate addition of grignard reagents to nitrodienes in the presence of catalytic amounts of Zn(II) salts

Grignard reagents undergo facile regioselective 1,4-conjugate addition to nitrodienes in the presence of catalytic amounts of Zn(II) salts with excellent yields. A wide range of ligands such as alkyl, aryl, heteroaryl, allyl, vinyl, 1-alkynyl, and alkoxy ligands were transferred, while a thiolate ligand afforded 1,6-regioselectivity. The reactions were successfully carried out on δ-alkyl- or aryl-substituted α,β,γ,δ-diunsaturated nitrodiene substrates. Regioselectivity is minimally influenced by temperature or choice of solvent.

Regio- and stereoselective 1,2-dihydropyridine alkylation/addition sequence for the synthesis of piperidines with quaternary centers

The first example of C alkylation of 1,2-dihydropyridines with alkyl triflates and Michael acceptors was developed to introduce quaternary carbon centers with high regio- and diastereoselectivity. Hydride or carbon nucleophile addition to the resultant iminium ion also proceeded with high diastereoselectivity. Carbon nucleophile addition results in an unprecedented level of substitution to provide piperidine rings with adjacent tetrasubstituted carbon atoms. Pipe up: Alkylation of readily prepared 1,2-dihydropyridines with alkyl triflates and Michael acceptors introduces quaternary carbon centers with high regio- and diastereoselectivity. Hydride or carbon nucleophile addition to the resultant iminium ion also proceeds with high diastereoselectivity. For carbon nucleophile addition, an unprecedented level of substitution is achieved to provide piperidine rings with contiguous tetrasubstituted carbon atoms.

S1P RECEPTORS MODULATORS AND THEIR USE THEREOF

The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.